ERBB2 and breast cancer: While not specifically asking the question of NLPD as a component of neoadjuvant CT, in the GeparSixto study, an intense CT backbone of 18 cycles of weekly paclitaxel 80 mg/m2 in combination with NPLD 20 mg/m2 in patients with triple-negative or HER2-positive (+) early-stage BC was administered [34].